{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-topical-skin-nose-eyes/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 465f3d21-5006-460a-818d-d530cc740703 --><h2>Changes</h2><!-- end field 465f3d21-5006-460a-818d-d530cc740703 -->","summary":null,"htmlStringContent":"<!-- begin item fc510145-c2a8-4e25-9ff1-4be2f02edb83 --><!-- begin field c9433c4b-69f3-42b4-95be-bcce4a2c1c97 --><p><strong>September 2020 </strong>— minor update. Contraindications and cautions of eye treatment updated in line with manufacturer's Summary of Product Characteristics.</p><p><strong>June 2020 </strong>— reviewed. A literature search was conducted in June 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. There have been no major changes to the recommendations.</p><!-- end field c9433c4b-69f3-42b4-95be-bcce4a2c1c97 --><!-- end item fc510145-c2a8-4e25-9ff1-4be2f02edb83 -->","topic":{"id":"091d926b-472d-55aa-b732-215f8299eb6e","topicId":"fe2967bf-dc0e-4dd2-903c-812a35c0d510","topicName":"Corticosteroids - topical (skin), nose, and eyes","slug":"corticosteroids-topical-skin-nose-eyes","lastRevised":"Last revised in September 2020","chapters":[{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"30c29984-be54-5cc7-b45b-ccea8330c500","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes"},{"id":"110d5d5e-8e14-51d5-ab15-5afa0d551cf7","slug":"update","fullItemName":"Update"}]},{"id":"6481ae53-8731-5bbf-84bb-f9c18452558f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"746ed409-c3cc-5d5f-a043-6c7e517b0f61","slug":"goals","fullItemName":"Goals"},{"id":"40ab5ace-33b8-5a2c-a6bb-cbd7fe8ca07c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc1a105d-dd83-5e54-b930-588a3dbdb5cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f6a0228b-0765-5b1b-b1b7-25eca749a1ab","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"842d280b-d84c-5903-bbdb-3f4fe26412fc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"17589721-7493-5da3-8828-e2b4bec649b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e28586d8-7d65-5f08-a10b-d2d25b975112","slug":"definition","fullItemName":"Definition"},{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids"},{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability"}]},{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment"},{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment"},{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment"}]},{"id":"ebd50a03-95ac-50a9-8a2d-4d615c9569bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0620ec75-3526-5198-b134-4f31d225ab30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2b03e883-8770-59d5-9965-04ffada0e471","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73e06218-1739-5de2-908f-ba65ba970168","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f813f700-2fb0-5989-90bd-2c2aa6dbb85a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3aa0e05-0446-53c0-9de1-2a8d2a9d1a70","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2a6ead30-5d09-5a96-b6d4-b673b755b98a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e78ffc84-8544-5685-8a35-65c8f05aac92","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"25ad4023-c53e-50d7-a2b6-2eaed763f2dd","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 82a044f9-1e97-4332-906c-eab219168ada --><h3>Previous changes</h3><!-- end field 82a044f9-1e97-4332-906c-eab219168ada -->","summary":null,"htmlStringContent":"<!-- begin item f2563c60-79d3-4275-9722-84cb602d85ba --><!-- begin field 34a94af7-cfda-44e4-8d1a-9c2e831e1a94 --><p><strong>April 2020</strong> — minor update. Table 5 in the quantities to prescribe section was updated to clarify that the quantities referred to single daily use for 2 weeks. </p><p><strong>November 2018</strong> — minor update. Strengths and formulations updated in Table 2. Topical corticosteroids listed by potency class. </p><p><strong>August 2017 </strong>— minor update. Information added regarding adverse effects associated with oral corticosteroids according to updates to the manufacturer's summary of product characteristics. </p><p><strong>December 2016 </strong>— minor update. Information that any of the systemic adverse effects associated with oral corticosteroids could also occur with topical corticosteroids, has been added to this topic.</p><p><strong>July to September 2015 </strong>— reviewed. A literature search was conducted in June 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. There have been no major changes to the recommendations.</p><p><strong>January 2011 </strong>— changed the title of the topic to <em>Corticosteroids - topical (skin), nose, and eyes</em>. The initial title <em>C</em><em>orticosteroids - topical (skin, nose, and eyes) </em>was inappropriate because, for the purpose of this topic, topical refers to corticosteroid preparations used on the skin. The term 'intraocular corticosteroids' has been changed to 'corticosteroid eye preparations' throughout the document, as it is more accurate terminology.</p><p><strong>September 2010 </strong>—<strong> </strong>minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded prescribers that psychological and behavioural adverse effects may occur in association with the use of intranasal corticosteroids. Issued in September 2010.</p><p><strong>April to August 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 34a94af7-cfda-44e4-8d1a-9c2e831e1a94 --><!-- end item f2563c60-79d3-4275-9722-84cb602d85ba -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}